Technetium (99mTc) medronic acid
| Technetium (99mTc) medronic acid | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | Intravenous |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Technetium (99mTc) medronic acid is a radiopharmaceutical used primarily in nuclear medicine for bone imaging. It is a compound that combines technetium-99m (99mTc), a widely used radioisotope, with medronic acid, a phosphonate compound that targets bone tissue.
Mechanism of Action[edit]
Technetium (99mTc) medronic acid works by binding to the hydroxyapatite crystals in bone. The technetium-99m emits gamma radiation, which can be detected by a gamma camera. This allows for the visualization of bone structure and the identification of abnormalities such as bone metastases, fractures, and osteomyelitis.
Clinical Use[edit]
Technetium (99mTc) medronic acid is used in bone scintigraphy, a diagnostic imaging technique. It is particularly useful for detecting bone metastases in patients with cancer, evaluating unexplained bone pain, and diagnosing osteomyelitis.
Administration[edit]
The compound is administered intravenously. After injection, it typically takes about 2-4 hours for optimal imaging, as the radiopharmaceutical accumulates in the bone tissue.
Safety and Side Effects[edit]
Technetium (99mTc) medronic acid is generally well-tolerated. However, potential side effects include allergic reactions, injection site reactions, and, rarely, radiation exposure risks. It is contraindicated in patients with known hypersensitivity to any component of the formulation.
Related Pages[edit]
Categories[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
